What are the indications, dosing regimen, renal and hepatic adjustments, contraindications, and common adverse effects of teneligliptin (a dipeptidyl‑peptidase‑4 inhibitor) in adults with type 2 diabetes?

Teneligliptin: Clinical Overview for Type 2 Diabetes Management

Teneligliptin is a DPP-4 inhibitor indicated for glycemic control in adults with type 2 diabetes, typically as add-on therapy when metformin and SGLT2 inhibitors are insufficient or not tolerated, though it offers no cardiovascular or renal outcome benefits and should not be prioritized over agents with proven mortality reduction.

Indications

Teneligliptin is approved for improving glycemic control in adults with type 2 diabetes mellitus as:

• Monotherapy with diet and exercise
• Combination therapy with metformin, sulfonylureas, thiazolidinediones, or insulin 1

However, current guidelines position DPP-4 inhibitors as third-line or later options 2, 3. The 2025 ADA Standards recommend prioritizing SGLT2 inhibitors and GLP-1 receptor agonists first due to their proven cardiovascular and renal benefits 2. The 2024 American College of Physicians guideline explicitly recommends against adding DPP-4 inhibitors to metformin to reduce morbidity and mortality (strong recommendation, high-certainty evidence) 4.

Clinical Positioning

Use teneligliptin when:

• Patient requires additional glucose-lowering beyond metformin/SGLT2i but cannot tolerate GLP-1 agonists
• Cost is prohibitive for preferred agents
• Patient refuses injectable therapy and oral GLP-1 agonists are unavailable
• Need to avoid hypoglycemia risk (unlike sulfonylureas) 2

Dosing Regimen

Standard dose: 20 mg orally once daily

• May increase to 40 mg once daily if needed for glycemic control 1, 5
• Can be taken with or without food
• Timing: Once-daily administration, preferably before breakfast, provides sustained postprandial glucose control throughout the day 5

Efficacy Expectations

• HbA1c reduction: 0.8-0.9% within 12 weeks 1, 6
• Fasting plasma glucose reduction: approximately 18 mg/dL 6
• 2-hour postprandial glucose reduction: approximately 47 mg/dL 6
• Effects sustained at 52 weeks in extension studies 1, 7

Important caveat: After 36-42 weeks, HbA1c levels may rise higher than during the initial double-blind period, suggesting potential durability concerns 6.

Renal Dose Adjustments

This is teneligliptin's key advantage: No dose adjustment required for any degree of renal impairment 1, 5, 8.

Unlike other DPP-4 inhibitors:

• Sitagliptin: Reduce to 50 mg with eGFR 30-44,25 mg with eGFR <30 9
• Saxagliptin: Reduce to 2.5 mg with eGFR <45 9
• Alogliptin: Reduce to 12.5 mg with eGFR 30-44,6.25 mg with eGFR <30 9
• Linagliptin: No adjustment needed (similar to teneligliptin) 2

Teneligliptin can be safely used in:

• Mild, moderate, or severe renal impairment
• End-stage renal disease
• Hemodialysis patients 1, 8

In a prospective study of 14 hemodialysis patients, teneligliptin 20 mg once daily significantly improved glycemic control (glycated albumin decreased by 3.1%, p<0.05) without hypoglycemia 8.

Hepatic Dose Adjustments

No dose adjustment required for mild-to-moderate hepatic impairment 1.

Teneligliptin undergoes both renal and hepatic elimination, which explains why renal impairment doesn't necessitate dose reduction 5. However, data in severe hepatic impairment are limited—use with caution in this population.

Contraindications

Absolute contraindications:

• Hypersensitivity to teneligliptin or any component
• Type 1 diabetes mellitus
• Diabetic ketoacidosis

Relative contraindications/cautions:

• Patients prone to QT prolongation (teneligliptin-specific concern) 5
• History of pancreatitis (class effect concern, though causality not established) 2
• Active bullous pemphigoid (discontinue if suspected) 2

Adverse Effects

Common Adverse Effects

Most frequent:

• Hypoglycemia (especially when combined with sulfonylureas or insulin) 1, 6
• Constipation 1
• Nasopharyngitis
• Upper respiratory tract infections 7

The overall adverse event profile is similar to placebo in meta-analysis (RR 0.96,95% CI 0.87-1.06, p=0.06) 6. Most events are mild intensity, with few discontinuations 7.

Serious Adverse Effects (Class Effects)

Pancreatitis: Acute pancreatitis has been reported with DPP-4 inhibitors, though causality remains unestablished 2. Discontinue immediately if pancreatitis is suspected. Do not initiate in patients at high risk for pancreatitis.

Arthralgia: Severe, debilitating joint pain has been reported postmarketing 2. Consider discontinuing if debilitating and other treatment options are feasible.

Bullous pemphigoid: Rare but serious skin reaction 2. Discontinue if suspected.

Cardiovascular Safety

Unlike SGLT2 inhibitors and GLP-1 agonists, DPP-4 inhibitors show neutral cardiovascular effects 2. One meta-analysis noted one cerebral infarction event 10, but large cardiovascular outcome trials have not demonstrated increased CV risk with the DPP-4 class overall 11.

Critical distinction: Some DPP-4 inhibitors (saxagliptin) have shown increased hospitalization for heart failure in specific trials 11. This appears to be a compound-specific rather than class effect. Teneligliptin-specific cardiovascular outcome data are limited.

Weight Effects

Weight neutral 2—neither weight gain nor loss expected, unlike:

• SGLT2 inhibitors and GLP-1 agonists (weight loss)
• Sulfonylureas, thiazolidinediones, insulin (weight gain)

Clinical Pearls

When to Use Teneligliptin

1. Renal impairment: When you need glucose-lowering in advanced CKD but SGLT2i/GLP-1 agonist are contraindicated or not tolerated
2. Hypoglycemia avoidance: Patient on insulin/sulfonylurea needs additional agent without increasing hypoglycemia risk
3. Cost constraints: In resource-limited settings where preferred agents are unaffordable 1

When NOT to Use Teneligliptin

1. Established cardiovascular disease: Use SGLT2i or GLP-1 agonist instead for mortality benefit 2, 4
2. Heart failure: Use SGLT2i for proven HF hospitalization reduction 2, 3
3. CKD with albuminuria: Use SGLT2i for renal protection 2, 3
4. First-line therapy: Metformin remains first-line; add SGLT2i second 3

Combination Therapy Considerations

With sulfonylureas or insulin: Reduce dose of these agents to minimize hypoglycemia risk when adding teneligliptin 12.

Triple therapy data: A 2025 study showed metformin + teneligliptin + glimepiride achieved HbA1c of 6.56% at 12 months without serious hypoglycemia 12, but this combination should be reserved for patients who cannot access preferred agents.

Monitoring

• Baseline: HbA1c, renal function, hepatic function
• Follow-up: HbA1c every 3 months until stable, then every 6 months
• No routine monitoring of renal/hepatic function required unless clinically indicated
• Watch for signs/symptoms of pancreatitis (severe abdominal pain)

Key Limitations

The fundamental issue with teneligliptin and all DPP-4 inhibitors is lack of outcome benefit beyond glucose-lowering 2, 4. While they improve HbA1c comparably to other agents, they do not reduce:

• All-cause mortality
• Major adverse cardiovascular events
• Progression of chronic kidney disease
• Heart failure hospitalizations

This stands in stark contrast to SGLT2 inhibitors and GLP-1 agonists, which demonstrate significant reductions in these hard outcomes 2, 3, 4.

Bottom line: Teneligliptin is a safe, well-tolerated glucose-lowering agent with the unique advantage of no renal dose adjustment, making it useful in advanced CKD when preferred agents cannot be used. However, it should not displace SGLT2 inhibitors or GLP-1 agonists in patients who could benefit from their proven cardiovascular and renal protection.